Skip to main content
Log in

The Authors’ Reply

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics 2005; 23 (12): 1271–1282

    Article  PubMed  CAS  Google Scholar 

  2. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess 2006; 10 (1): iii–iv, ix-xi, 1-160

    PubMed  CAS  Google Scholar 

  3. Bosanquet N, Yeates A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease Detter]. Pharmacoeconomics 2006; 24 (6): 623–625

    Article  PubMed  Google Scholar 

  4. National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk/page.aspx?O=appraisals.inprogress.alzheimersdisease [Accessed 2006 May 19]

Download references

Acknowledgements

The authors have no conflicts of interest relevent to the content of this reply.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, C., Picot, J., Loveman, E. et al. The Authors’ Reply. Pharmacoeconomics 24, 625–626 (2006). https://doi.org/10.2165/00019053-200624060-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624060-00009

Keywords

Navigation